Jyong Biotech Ltd. Ordinary Shares logo

Jyong Biotech Ltd. Ordinary Shares(MENS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.76
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for MENS

11/13/2026: MENS (1-star) is currently NOT-A-BUY. Pass it for now.

Jyong Biotech Ltd. is a Taiwan-based, clinical-stage biotechnology company focused on developing botanical drugs for urinary system diseases, such as BPH. The company's primary strength is its proprietary chylomicron platform, which aims to improve the safety and efficacy of plant-derived therapeutics. Its main growth story centers on the potential FDA approval of its lead candidate, BOTRESO, and planned U.S. manufacturing expansion. However, significant risks include a history of clinical trial failures, high cash burn, and intense competition from large pharmaceutical incumbents. This stock is suitable for speculative investors who understand the high-risk, binary nature of biotechnology investments, and shareholders should monitor regulatory milestones and partnership updates closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high growth potential contingent upon binary clinical trial and regulatory outcomes, which is typical for speculative biotech.
Momentum investorWeak fitThe stock has experienced extreme volatility and downward trends, making it unsuitable for momentum strategies without a clear, sustained upturn.
Value investorWeak fitThe company lacks current earnings, stable cash flows, or established assets to support a traditional value-based investment thesis.
Dividend investorWeak fitJyong Biotech does not pay dividends and is not expected to do so in the near future.
Low-risk investorWeak fitThe high volatility and binary nature of development-stage biotech make this stock inappropriate for low-risk, capital-preservation portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock is subject to massive price swings based on clinical news, making it highly unpredictable for retail investors.
Valuation riskHighWithout commercial revenue, valuation is speculative and largely dependent on future potential that may never materialize.
Competition risk (Biopharma)HighEstablished pharmaceutical firms have greater resources to market competitive treatments for urinary conditions.
Business qualityMediumThe company has dedicated 20 years to building its R&D platform, though this has yet to be validated by commercial success.
Dividend incomeLow / noneThere is no income potential for shareholders, as the company is entirely focused on R&D investment.
Execution riskHighThe company must successfully navigate FDA clinical trials and build U.S. operations, both of which are fraught with execution challenges.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 133.81M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 41.9K shares
Beta -
52 Weeks Range 1.43 - 40.25
Updated Date 11/14/2026
52 Weeks Range 1.43 - 40.25
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.06

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 49.67%
Avg. Invested days 13
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
MENS receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
MENS has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-54.7%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
MENS's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is MENS's strongest growth driver at +16.1% FY2025 versus FY2024 (solid, 4 stars). By comparison, while revenue growth (+0.0%, slightly negative) and earnings growth (-54.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 0.8% (soft) and 36.3% of outstanding shares are publicly tradable (moderate). Insider ownership of 62.20% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 0.35%
Geode Capital Management, LLC 0.09%
HRT FINANCIAL LLC 0.07%
XTX Topco Ltd 0.04%
Renaissance Technologies Corp 0.03%

Unit Economics (Per $1K Revenue)

★★★★★
MENS generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
MENS has a relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Research & DevelopmentFocuses on scientific drug discovery and clinical trials for proprietary botanical candidates.Currently, the company does not make money; it spends money to develop potential future drugs.
Pharmaceutical PreparationsDeveloping commercialization pathways for products like BOTRESO.This is the future revenue engine, contingent upon regulatory approval.
Geography: U.S. & InternationalOperations in Taiwan, Singapore, China, and planned expansion into Texas, U.S.The company is targeting the U.S. market as its highest-priority area for future drug sales.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 142.09M
Price to Sales(TTM) -
Enterprise Value 142.09M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 74.23M
Shares Floating 26.94M
Shares Outstanding 74.23M
Shares Floating 26.94M
Percent Insiders 62.2
Percent Institutions 0.78

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.